IL17A and psoriasis: In recent years, biological agents (e.g. TNFα inhibitors, IL-23 inhibitors, IL-17 inhibitors, and IL-12/23 inhibitors) have become important treatments for patients with moderate to severe psoriasis, which block the proinflammatory cytokines and lymphocyte activation in psoriasis [3–6].